Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 15, 2021 - Issue
Submit an article Journal homepage
150
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Effect of Different Dosage Frequency of Polymyxin B on Rat Nephrotoxicity

Wenrui Sun1 The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People’s Republic of China
,
Binchuan Hu2 Yongjia People’s Hospital, Wenzhou, 325100, People’s Republic of China
,
Xiaoshan Zhang1 The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People’s Republic of China;3 Wenzhou Medical University, Wenzhou, 325000, People’s Republic of China
,
Yuzhen Wang1 The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People’s Republic of China;3 Wenzhou Medical University, Wenzhou, 325000, People’s Republic of China
,
Zheng Xiang3 Wenzhou Medical University, Wenzhou, 325000, People’s Republic of China
&
Guanyang Lin1 The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People’s Republic of ChinaCorrespondence[email protected]
Pages 611-616 | Published online: 16 Feb 2021

References

  • SolomonSL, OliverKB. Antibiotic resistance threats in the United States: stepping back from the brink. Am Fam Physician. 2014;89(12):938–941.25162160
  • AvedissianSN, LiuJ, RhodesNJ, et al. A review of the clinical pharmacokinetics of polymyxin B. Antibiotics (Basel). 2019;8(1). doi:10.3390/antibiotics8010031.
  • TsujiBT, PogueJM, ZavasckiAP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39. doi:10.1002/phar.220930710469
  • AbdelraoufK, ChangKT, YinTJ, HuM, TamVH. Uptake of polymyxin B into renal cells. Antimicrob Agents Chemother. 2014;58(7):4200–4202. doi:10.1128/AAC.02557-1424733472
  • ManchandaniP, ZhouJ, LedesmaKR, et al. Characterization of polymyxin B biodistribution and disposition in an animal model. Antimicrob Agents Chemother. 2016;60(2):1029–1034. doi:10.1128/AAC.02445-1526643340
  • Vattimo MdeF, WatanabeM, da FonsecaCD, NeivaLB, PessoaEA, BorgesFT. Polymyxin B nephrotoxicity: from organ to cell damage. PLoS One. 2016;11(8):e0161057. doi:10.1371/journal.pone.016105727532263
  • AbdelraoufK, BraggsKH, YinT, TruongLD, HuM, TamVH. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother. 2012;56(9):4625–4629. doi:10.1128/AAC.00280-1222687519
  • OkoduwaA, AhmedN, GuoY, et al. Nephrotoxicity associated with intravenous polymyxin B once- versus twice-daily dosing regimen. Antimicrob Agents Chemother. 2018;62(8). doi:10.1128/AAC.00025-18.
  • ManchandaniP, ZhouJ, BabicJT, LedesmaKR, TruongLD, TamVH. Role of renal drug exposure in polymyxin B-induced nephrotoxicity. Antimicrob Agents Chemother. 2017;61(4). doi:10.1128/AAC.02391-16
  • LiuJ, PaisGM, AvedissianSN, et al. Evaluation of dose-fractionated polymyxin B on acute kidney injury using a translational in vivo rat model. Antimicrob Agents Chemother. 2020;64(5). doi:10.1128/AAC.02300-19.
  • AggarwalR, DewanA. Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study. Ann Clin Microbiol Antimicrob. 2018;17(1):15. doi:10.1186/s12941-018-0262-029571295
  • SoaresDS, ReisADF, Silva JuniorGBD, et al. Polymyxin-B and vancomycin-associated acute kidney injury in critically ill patients. Pathog Glob Health. 2017;111(3):137–142. doi:10.1080/20477724.2017.130933828353411
  • WallaceSJ, LiJ, NationRL, et al. Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimens. Antimicrob Agents Chemother. 2008;52(3):1159–1161. doi:10.1128/AAC.01101-0718180359
  • NelsonBC, EirasDP, Gomez-SimmondsA, et al. Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods. Antimicrob Agents Chemother. 2015;59(11):7000–7006. doi:10.1128/AAC.00844-1526324272
  • YunB, ZhangT, AzadMAK, et al. Polymyxin B causes DNA damage in HK-2 cells and mice. Arch Toxicol. 2018;92(7):2259–2271. doi:10.1007/s00204-018-2192-129556720
  • AzadMA, AkterJ, RogersKL, NationRL, VelkovT, LiJ. Major pathways of polymyxin-induced apoptosis in rat kidney proximal tubular cells. Antimicrob Agents Chemother. 2015;59(4):2136–2143. doi:10.1128/AAC.04869-1425624331
  • WeberEJ, LidbergKA, WangL, et al. Human kidney on a chip assessment of polymyxin antibiotic nephrotoxicity. JCI Insight. 2018;3(24). doi:10.1172/jci.insight.123673.
  • AbdelraoufK, HeJ, LedesmaKR, HuM, TamVH. Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob Agents Chemother. 2012;56(11):5724–5727. doi:10.1128/AAC.01333-1222908162

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.